MedDay of France, which is preparing a European filing for its progressive multiple sclerosis product MD1003, has raised €34m in a Series B financing round. Edmond de Rothschild Investment Partners (EDRIP) led the new investment round alongside existing investors Sofinnova Partners, the company's largest shareholder, and InnoBio (Bpifrance). Large Venture (Bpifrance) also participated.
MedDay Raises €34m For US Trial As EU Filing Of MS Drug Nears
MedDay of France, which is preparing a European filing for its progressive multiple sclerosis product MD1003, has raised €34m in a Series B financing round. Edmond de Rothschild Investment Partners (EDRIP) led the new investment round alongside existing investors Sofinnova Partners, the company's largest shareholder, and InnoBio (Bpifrance). Large Venture (Bpifrance) also participated.
More from Neurological
More from Therapy Areas
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.